BLO Cannabix Technologies Inc

Cannabix Technologies Announces First Sale of BreathLogix Alcohol Screening Device to Maritime Market

Cannabix Technologies Announces First Sale of BreathLogix Alcohol Screening Device to Maritime Market

VANCOUVER, British Columbia, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath devices is pleased to report that it has entered into its first sale agreement for its BreathLogix unmanned alcohol screening technology. The Company will be delivering its BreathLogix technology to a European maritime shipping company that is seeking to increase operational safety amongst its crew members with pre-access breath alcohol testing. The system will be integrated with the cloud-based “BreathLogix Connect” platform, powered by Amazon Web Services, enabling real-time alerts, centralized data management, and seamless reporting. Additionally, the device will integrate facial recognition technology for rapid and secure crew member identification. The BreathLogix alcohol testing solution is targeted to various industries including mining, oil and gas, industrial, trucking, warehousing and maritime vessels to enhance operational safety.

Figure 1. BreathLogix Alcohol device available with contactless and straw modes for rapid workplace pre-access alcohol screening

This announcement comes on the heels of the Company completing its first commercial production run commenced this summer. Earlier this year, the Company’s BreathLogix “Workplace Series” device was approved by National Highway Traffic Safety Association (NHTSA) to be added to the U.S. Federal Register Conforming Products List (CPL) for breath alcohol screen devices.

BreathLogix unmanned alcohol screening devices rapidly check for breath alcohol and simultaneously takes a photo of the user to help confirm and record identity (Figure 1 and 2). The device delivers precise Blood Alcohol Content (BAC or BrAC) levels on the screen and sends real-time test reports via SMS and e-mail, alerting managers to positive BAC results so they can take immediate action to avoid damage and injury. All test results are logged and managed on a dedicated ‘BreathLogix Connect’ web portal. BreathLogix can be integrated with doors, turnstiles, gates, facial recognition, fingerprint readers and motor vehicle key fleet management systems for pre-access alcohol testing. Furthermore, the device can be used for start-of-shift testing, mandated testing, pre-employment testing, return-to-work testing, random and post-incident testing.

BreathLogix includes patent pending pre-calibrated sensor cartridge technology allowing administrators to easily maintain their devices and eliminate the need for costly calibration equipment and time-consuming site visits from technicians for maintenance.   

Figure 2. BreathLogix Alcohol Screening Devices by Cannabix Technologies Inc.

We seek Safe Harbor.

On behalf of the Board of Directors

“Rav Mlait”

CEO

Cannabix Technologies Inc.

For further information, contact the Company at

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements



This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements relating to: certification of devices, acceptance of devices by international regulators, the achievement of any or all of the goals and aims of the distribution and sales agreement with any third-party companies; positive developments with contract manufacturers; the completion of pre-validation or validation testing; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company's products; the negotiation and potential entry into additional agreements with distributors and or contract manufacturers; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are note limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that the Company’s development of cannabis and alcohol breathalyzer technologies will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any “patent pending” or “provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breathalyzers and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

Photos accompanying this announcement are available at



EN
30/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cannabix Technologies Inc

 PRESS RELEASE

Cannabix Technologies Announces First Sale of BreathLogix Alcohol Scre...

Cannabix Technologies Announces First Sale of BreathLogix Alcohol Screening Device to Maritime Market VANCOUVER, British Columbia, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath devices is pleased to report that it has entered into its first sale agreement for its BreathLogix unmanned alcohol screening technology. The Company will be delivering its BreathLogix technology to a European maritime shipping company that is seeking to increase operational safety amo...

 PRESS RELEASE

Cannabix Technologies to Participate at U.S. National Institute of Sta...

Cannabix Technologies to Participate at U.S. National Institute of Standards and Technology (NIST) Cannabis Breathalyzer Workshop VANCOUVER, British Columbia, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath testing devices reports that it will be attending the inaugural “Building a Path Forward for Meaningful Cannabis Breathalyzer Realization” workshop hosted by the United States National Institute of Standards and Technology (“NIST”). NIST, a federal agency u...

 PRESS RELEASE

Cannabix Technologies to Exhibit at National Safety Council (NSC) Safe...

Cannabix Technologies to Exhibit at National Safety Council (NSC) Safety Congress and Expo, Denver Colorado VANCOUVER, British Columbia, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath testing devices is pleased to report its participation in the NSC Safety Congress & Expo, taking place September 15–17, 2025 in Denver, Colorado. The NSC Safety Congress & Expo is the world’s largest annual event dedicated to workplace safety, health, and environmental profession...

 PRESS RELEASE

Cannabix Technologies delivers Marijuana Breath Test Hardware to Omega...

Cannabix Technologies delivers Marijuana Breath Test Hardware to Omega Laboratories Inc. VANCOUVER, British Columbia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) reports that it has delivered multiple Cannabix Marijuana Breath Test (“MBT”) units to Omega Laboratories Inc. of Ohio, USA (“Omega Laboratories” or “Omega”) to initiate phased commercialization efforts. The MBT hardware includes Cannabix’s proprietary Breath Collection Unit (BCU) and Breath Cartridges (BC) technology which are designed to ...

 PRESS RELEASE

Bill Corl of Omega Laboratories Joins Cannabix Technologies Board of D...

Bill Corl of Omega Laboratories Joins Cannabix Technologies Board of Directors VANCOUVER, British Columbia, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) is pleased to announce William (Bill) R. Corl has joined the board of directors of the Company. Mr. Corl is the Chief Executive Officer for Omega Laboratories, Inc., (“Omega”) one of the leading advanced specimen drug testing laboratories in the world. Omega and Cannabix have been working together since May 2024 under a strategic partnership and deve...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch